Study of ONO-8539 in Patients With Overactive Bladder

Phase 2

Completed

• Conditions: Overactive Bladder
• Interventions: Drug: Placebo; Drug: Tolterodine; Drug: ONO-8539

• Registration Number: NCT00876421
• Lead Sponsor: Ono Pharmaceutical Co. Ltd

Brief Summary

The objective of this study is to investigate efficacy, safety and tolerability of ONO-8539 in patients with overactive bladder.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-04
• Study First Submitted: 2009-04-02
• Study First Submitted QC: 2009-04-03
• Study First Posted: 2009-04-06
• Primary Completion: 2010-04
• Status Verified: 2012-06
• Last Update Submitted: 2012-06-12
• Last Update Posted: 2012-06-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 435

Inclusion Criteria

• Patients with medical history of Overactive Bladder symptoms for > 6 months

Exclusion Criteria

• Patients who have a history or presence of other significant diseases, which in the opinion of the investigator, might compromise the patient's safety or the evaluation of the study results

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
P	Placebo	-
A	Tolterodine	-
E3	ONO-8539	-
E1	ONO-8539	-
E2	ONO-8539	-

Primary Outcome Measures

Name	Time	Method
Overactive bladder symptoms	12 weeks

Secondary Outcome Measures

Name	Time	Method
Overactive bladder symptoms (QOL)	12 weeks